

No.	API	Chinese Name	CAS No.	Specification	Statement
A01	Mavacamten	玛伐凯泰	1642288-47-8	In-house	DMF Submitted
A02	Azilsartan Medoxomil Potassium	美阿沙坦钾	863031-24-7	In-house	DMF Submitted
A03	Venetoclax	维奈克拉	1257044-40-8	In-house	DMF Submitted
A04	Zavegepant Hydrochloride	盐酸扎维吉泮	1414976-20-7	In-house	DMF Submitted
A05	Deucravacitinib	氘可来昔替尼	1609392-27-9	In-house	DMF Submitted
No.	Intermediate	CAS No.	Specification	Related API	Statement
M01	4-Hydroxybenzenecarbothioamide	25984-63-8	In-house	Febuxostat	Commercial batches
M02	Ethyl 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylate	161797-99-5	In-house	Febuxostat	Commercial batches
M03	Ethyl 2-(3-Formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate	161798-01-2	In-house	Febuxostat	Commercial batches
M04	Ethyl 2-(3-formyl-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate	161798-03-4	In-house	Febuxostat	Commercial batches
M05	Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate	160844-75-7	In-house	Febuxostat	Commercial batches
M06	Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate	139481-44-0	In-house	Candesartan cilexetil	Commercial batches
M07	Ethyl-2-Ethoxy-1-[[[2'-Cyanobiphenyl-4-yl] Methyl] Benzimidazole]-7-Carboxylate	139481-41-7	In-house	Candesartan cilexetil	Commercial batches
M08	4,6-Dichloro-5-methoxypyrimidine	5018-38-2	In-house	Sulfadoxine	Commercial batches
M09	5,6-Dichloro-N-[4-(4-Chlorothien-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]pyridine-3-carboxamide	570403-04-2	In-house	Avatrombopag maleate	Approved by NMPA
M10	tert-Butyl 3-(cyanomethyl)-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate	1627504-41-9	In-house	Baricitinib	Approved by NMPA
M11	4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl]piperazin-1-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzoic acid	1235865-77-6	In-house	Venetoclax	DMF dual filing in China and the US completed
M12	1H-pyrrolo[2,3-b]pyridin-5-ol	98549-88-3	In-house	Venetoclax	DMF dual filing in China and the US completed
M13	3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide	1228779-96-1	In-house	Venetoclax	DMF dual filing in China and the US completed
M14	4'-chloro-5,5-diMethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-carbaldehyde	1228837-05-5	In-house	Venetoclax	DMF dual filing in China and the US completed
M15	1-(((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine	1228780-72-0	In-house	Venetoclax	DMF dual filing in China and the US completed
M16	methyl (R)-3-(7-methyl-1H-indazol-5-yl)-2-(4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamido)propanoate	928014-64-6	In-house	Zavegepant hydrochloride	DMF dual filing in China and the US completed
M17	(R)-2-(4-(1,2-dihydro-2-oxoquinolin-3-yl)piperidine-1-carboxamido)-3-(7-methyl-1H-indazol-5-yl)propanoic acid	N/A	In-house	Zavegepant hydrochloride	DMF dual filing in China and the US completed
M18	6-chloro-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione	887581-47-7	In-house	Mavacamten	DMF submitted
M19	Methyl 6-chloro-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)pyridazine-3-carboxylate	2720564-44-1	In-house	Deucravacitinib	DMF submitted, China DMF to be submitted
M20	Methyl 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)pyridazine-3-carboxylate	3036620-17-1	In-house	Deucravacitinib	DMF submitted, China DMF to be submitted
M21	((1R,2S)-1-(3-(benzyloxy)phenyl)-1-hydroxypropan-2-yl)carbamate benzyl	31301-86-7	In-house	Metaraminol bitartrate	Filed in China, pending approval
M22	2-(2-hydroxyphenyl)-4H-benzo[c][1,3]oxazin-4-one	1218-69-5	In-house	Deferasiroxum	Under deficiency review in NMPA
M23	(3R,4S)-3-(2-Bromoacetyl)-4-ethyl-1-pyrrolidinecarboxylic acid phenylmethyl ester	1428243-26-8	In-house	Upadacitinib	Under deficiency review in China
M24	Tert-butyl 5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-ylcarbamate	1201187-44-1	In-house	Upadacitinib	Under deficiency review in China
M25	(3S,4R)-benzyl 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-c]pyrazin-8-yl)pyrrolidine-1-carboxylate	2095311-51-4	In-house	Upadacitinib	Under deficiency review in China